<DOC>
	<DOCNO>NCT01860430</DOCNO>
	<brief_summary>This clinical trial aim establish recommend start dose ipilimumab future efficacy trial use combination intensity modulate radiation therapy ( IMRT ) cetuximab .</brief_summary>
	<brief_title>A Phase Ib Trial Concurrent Cetuximab ( ERBITUX® ) Intensity Modulated Radiotherapy ( IMRT ) With Ipilimumab ( YERVOY® ) Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>The investigator propose integrate anti-CTLA-4 specific mAb , ipilimumab , standard regimen cetuximab plus RT ( 70-74.0 Gy ) dose find , phase I trial , inform design future phase II clinical trial would determine clinical efficacy .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>AJCC stage III/IVB , exclude T1N1 , histologically cytologically confirm squamous cell carcinoma undifferentiated carcinoma head neck . Patients distant metastasis . Primary site include : oropharynx , hypopharynx , larynx Patients must high intermediate risk disease , define follow : High risk : p16 Intermediate risk : p16+ , ≥ 10 packyear tobacco exposure ≥ N2 disease . Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record nonnodal lesion short axis nodal lesion ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan , MRI , caliper clinical exam . See Section 11 evaluation measurable disease . Patients newly diagnose HNSCC , prior therapy disease . Age &gt; 18 year . ECOG performance status typically &lt; 1 ( Karnofsky &gt; 70 % ) Patients must acceptable organ marrow function define : leukocyte &gt; 3,000/mcL absolute neutrophil count &gt; 1,200/mcL platelet &gt; 75,000/mcL total bilirubin ≤ 2 mg/dL ( ≤ 3 mg/dL case gilbert 's syndrome ) AST/ALT ≤ 2 time institutional ULN creatinine clearance &gt; 40 mL/min/1.73 m2 Patients must ability understand sign write informed consent . Patients prior chemotherapy , radiotherapy , surgery curative intent HNSCC . Patients history prior treatment ipilimumab , antiPD 1 antibody , CD137 agonist immune activate therapy antiCD 40 antibody . Patients receive investigational agent . Autoimmune disease : Patients history inflammatory bowel disease , include ulcerative colitis Crohn 's Disease , exclude study , patient history symptomatic nongastrointestinal autoimmune disease ( e.g. , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ e.g. , Wegener 's Granulomatosis ] ) ; CNS motor neuropathy consider autoimmune origin ( e.g . GuillainBarre Syndrome Myasthenia Gravis , multiple sclerosis. ) . Patients known immunodeficiency disorder , presume unable respond antiCTLA4 mAb Patients distant metastatic disease ( stage IVC ) . History allergic reaction attribute compound similar chemical biologic composition cetuximab ipilimumab . Patient &lt; 2 year free second primary malignancy unless malignancy nonmelanomatous skin cancer insitu tumor treat curative intent . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Patients chronic Hepatitis B hepatitis C infection exclude potential effect immune function and/ drug interaction , well potential confound interpretation immunerelated adverse event hepatic inflammation occur protocol . Pregnant woman exclude study ipilimumab may potential teratogenic abortifacient effect . These potential risk may also apply agent use study . HIVpositive patient combination antiretroviral therapy ineligible potential pharmacokinetic interaction ipilimumab immunosuppressed individual . Appropriate study undertake patient receive combination antiretroviral therapy indicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Locally Advanced</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Ipilimumab ( YERVOY® )</keyword>
</DOC>